Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV ActivityAnita Mathias, Brian P. Kearney, David R. Warren et al.|Clinical Pharmacology & Therapeutics|2009Cited by 208
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Brian P. Kearney, Kitty Yale et al.|AIDS|2011Cited by 109
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionRichard Elion, David R. Warren, Brian P. Kearney et al.|AIDS|2011Cited by 92